Uganda & Regeneron Pharmaceuticals

Uganda: Uganda has confirmed imported Ebola cases from the Democratic Republic of the Congo, leading to heightened surveillance, travel restrictions, and the postponement of national events to prevent further spread.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Uganda: Uganda has reported cases of the Bundibugyo strain of Ebola, making it a focus for the World Health Organization's efforts to implement clinical trials for experimental treatments and vaccines.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.